Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heart Failure and Reduced Ejection Fraction Clear all
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction

NCT04836182
View directory record Official record
Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
IONIS-AGT-LRx, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Little Rock, Arkansas • Crystal River, Florida • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Jun 10, 2026, 5:23 AM EDT
Completed Phase 4 Interventional Results available

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

NCT02874794
View directory record Official record
Conditions
Heart Failure and Reduced Ejection Fraction
Interventions
LCZ696 (sacubitril/valsartan), Enalapril, Placebo of Enalapril, Placebo of LCZ696
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
81
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jun 10, 2026, 5:23 AM EDT
Completed Not applicable Interventional

Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)

NCT01354613
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
Interventions
Dobutamine, Amlodipine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Jun 10, 2026, 5:23 AM EDT
Recruiting Phase 3 Interventional

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
5,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
106
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 5:23 AM EDT
Recruiting Phase 3 Interventional

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197
View directory record Official record
Conditions
Heart Failure, Acute Heart Failure
Interventions
Finerenone, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
5,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
77
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 10, 2026, 5:23 AM EDT
Completed No phase listed Observational

An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States

NCT06363110
View directory record Official record
Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
Vericiguat (Verquvo, BAY1021189)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jun 10, 2026, 5:23 AM EDT
Not yet recruiting Not applicable Interventional

Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart Failure

NCT07467668
View directory record Official record
Conditions
Iron Deficiency (ID), Heart Failure, Heart Failure and Reduced Ejection Fraction, Heart Failure and Mildly Reduced Ejection Fraction
Interventions
Notification Group, No Notification Group
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jun 10, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

NCT02226120
View directory record Official record
Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
LCZ696
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
1,980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
24
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Jun 10, 2026, 5:23 AM EDT
Withdrawn Phase 4 Interventional

Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure

NCT02767024
View directory record Official record
Conditions
Acute Heart Failure
Interventions
Sodium nitroprusside, Dobutamine, Furosemide
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Jun 10, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

NCT03888066
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer, Placebos
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
133
States / cities
Alexander City, Alabama • Huntsville, Alabama • Phoenix, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Jun 10, 2026, 5:23 AM EDT
Enrolling by invitation No phase listed Observational

Gut Microbiome Profiling in Patients With Chronic Heart Failure

NCT06361524
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Nonischemic Cardiomyopathy
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jun 10, 2026, 5:23 AM EDT
Completed Not applicable Interventional

Blood Volume and Hemodynamic Analysis in Patients With Chronic Heart Failure

NCT02120014
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
blood volume measurement, venous plethysmography
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Jun 10, 2026, 5:23 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists

NCT06033950
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
2,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Fairhope, Alabama • San Diego, California • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jun 10, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Results available

Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)

NCT04210375
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
JK07, Matching Placebo
Drug
Lead sponsor
Salubris Biotherapeutics Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Tucson, Arizona • Stanford, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Jun 10, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

CoQ10 and D-ribose in Patients With Diastolic Heart Failure

NCT03133793
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
CoQ10, D-Ribose Oral Powder, Placebo pills, Placebo powder
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
50 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Jun 10, 2026, 5:23 AM EDT
Completed Not applicable Interventional Results available

Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure (BETTER CARE-HF)

NCT05275920
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions
Best Practice Alert (BPA), In-Basket Message
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
2,211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jun 10, 2026, 5:23 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction

NCT03875183
View directory record Official record
Conditions
Heart Failure, Reduced Ejection Fraction
Interventions
INL1, Placebo
Drug · Other
Lead sponsor
Innolife Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Torrance, California • Clearwater, Florida • Doral, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jun 10, 2026, 5:23 AM EDT
Completed No phase listed Observational

Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure

NCT05077293
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions
Best Practice Alert (BPA), In-Basket Message
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Jun 10, 2026, 5:23 AM EDT
Enrolling by invitation Not applicable Interventional

Alleviant ALLAY-HFrEF Study

NCT06812533
View directory record Official record
Conditions
Heart Failure
Interventions
Alleviant ALV1 System, Sham-Control
Device · Other
Lead sponsor
Alleviant Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 10, 2026, 5:23 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease

NCT03551756
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease
Interventions
Biomarker Assessment
Other
Lead sponsor
CirQuest Labs, LLC
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Jacksonville, Florida • Germantown, Tennessee • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Jun 10, 2026, 5:23 AM EDT
Recruiting Not applicable Interventional

Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure

NCT06526988
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
EPIC-HF Patient-facing Tool, PROMPT-HF Clinician-facing Alert
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Walnut Creek, California • Aurora, Colorado • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jun 10, 2026, 5:23 AM EDT
Completed Early Phase 1 Interventional

Exercise and NO in HFrEF

NCT03136029
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Antioxidant, Tetrahydrobiopterin (BH4), Exercise training
Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jun 10, 2026, 5:23 AM EDT
Not listed Not applicable Interventional

Remote Monitoring of Multiple Indicators of Heart Failure

NCT04267744
View directory record Official record
Conditions
Heart Failure
Interventions
Myia Health® remote patient monitoring unblinded treatment arm
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Jun 10, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Results available

Ketone Pharmacokinetic Study in HFrEF

NCT05757193
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
DeltaG (250 mg/kg), DeltaG (500 mg/kg)
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jun 10, 2026, 5:23 AM EDT